Clinical Trial Update: A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS) [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study to evaluate safety and tolerability of LX214 ophthalmic solution in healthy volunteers, followed by open-label assessment in patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconjunctivitis Sicca

Drugs mentioned

• LX214 Ophthalmic Solution (LX214)

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Keratoconjunctivitis Sicca | Phase 1 | Status: COMPLETED